Supplementary Table 1. Baseline demographics in ultra-early vs 24-72h group			
	Ultra-early anticoagulation (n=111)	24-72h anticoagulation (n=30)	*P* value
Common patient characteristics			
Age, y	72 (63-78)	67 (60-77)	0.33
Male	44 (39.6%)	8 (26.7%)	0.19
Admission NIHSS	17 (12-22)	14 (12-19)	0.22
Ischemia in left hemisphere	58 (52.3%)	16 (53.3%)	0.92
Treatment with intravenous thrombolysis	52 (46.8%)	14 (46.7%)	0.99
Premorbid oral anti-thrombotic use	44 (39.6%)	6 (20.0%)	0.05*
Smoke	24 (21.6%)	4 (13.3%)	0.31
Hypertension	51 (45.9%)	13 (43.3%)	0.80
Diabetes mellitus	24 (21.6%)	8 (26.7%)	0.56
Previous stroke	12 (10.8%)	4 (13.3%)	0.70
Systolic blood pressure	143.72±23.84	138.27±22.09	0.26
Diastolic blood pressure	83.39±16.80	84.50±14.31	0.74
INR	1.04 (0.99-1.12)	1.06 (0.99-1.16)	0.41
Trombocyte count	165 (128-220)	196 (167-222)	0.06
Glucose level	7.35 (6.12-9.17)	8.50 (6.64-9.47)	0.10
CHA2DS2-VASc score	5 (3-5)	4 (3-5)	0.39
HASBLED score	3 (3-4)	4 (3-4)	0.36
Heparin during procedure	51 (45.9%)	13 (43.3%)	0.80
Tirofiban during procedure	31 (27.9%)	5 (16.7%)	0.21
Imaging			
ASPECETS	9 (8-10)	9 (8-9)	0.17
Occlusion site			0.55
ICA	32 (28.8%)	7 (23.3%)	
M1	58 (52.3%)	19 (63.3%)	
M2	21 (18.9%)	4 (13.4%)	
Reperfusion before intervention (mTICI)			0.09
0	97 (87.4%)	22 (73.3%)	
1	3 (2.7%)	5 (16.7%)	
2a	4 (3.6%)	1 (3.3%)	
2b	7 (6.3%)	2 (6.7%)	
Workflow (in minutes)			
Symptom onset to admission ER	201 (111-330)	225 (72-368)	0.79
Admission ER to groin puncture	118 (95-157)	130 (105-177)	0.21
Duration procedure	60 (40-96)	66 (40-129)	0.62
Symptom onset to reperfusion	410 (290-615)	449 (353-572)	0.30

Baseline variables with ultra-early and 24-72h anticoagulation group. *P<0.05. ASPECTS indicates Alberta Stroke Program Early Computed Tomography Score; ER, emergency room; ICA, internal carotid artery; INR, international normalized ratio; MCA-M1/M2, the first/second segment of middle cerebral artery; mTICI, modified thrombolysis in cerebral infarction; NIHSS, National Institutes of Health Stroke Scale.

Supplementary Table 2. Baseline demographics in UFH vs LMWH group			
	UFH group (n=69)	LMWH group (n=72)	*P* Value
Common patient characteristics			
Age, y	71 (61-78)	71 (62-78)	0.33
Male	27 (39.1%)	25 (34.7%)	0.59
Admission NIHSS	17 (13-22)	15 (12-20)	0.22
Ischemia in left hemisphere	37 (53.6%)	37 (51.4%)	0.79
Treatment with intravenous thrombolysis	33 (47.8%)	33 (45.8%)	0.81
Premorbid oral anti-thrombotic use	28 (40.6%)	22 (30.6%)	0.21
Smoke	10 (14.5%)	18 (25.0%)	0.12
Hypertension	35 (50.7%)	29 (40.3%)	0.21
Diabetes mellitus	15 (21.7%)	17 (23.6%)	0.79
Previous stroke	4 (5.8%)	12 (16.7%)	0.04*
Systolic blood pressure	144.99±24.88	140.24±22.03	0.23
Diastolic blood pressure	82.94±17.79	84.28±14.74	0.63
INR	1.04 (0.98-1.11)	1.05 (1.00-1.13)	0.41
Trombocyte count	171 (132-225)	182 (143-220)	0.06
Glucose level	7.30 (6.17-9.50)	8.00 (6.10-9.20)	0.10
CHA2DS2-VASc score	4 (3-5)	5 (3-5)	0.39
HASBLED score	3 (3-4)	3 (3-4)	0.36
Heparin during procedure	35 (50.7%)	29 (40.3%)	0.21
Tirofiban during procedure	21 (30.4%)	15 (20.8%)	0.19
Imaging			
ASPECETS	9 (8-10)	9 (8-10)	0.17
Occlusion site			0.07
ICA	24 (34.8%)	15 (20.8%)	
MCA-M1	31 (44.9%)	46 (63.9%)	
MCA-M2	14 (20.3%)	11 (15.3%)	
Reperfusion before intervention (mTICI)			0.68
0	59 (85.5%)	60 (83.3%)	
1	4 (5.8%)	4 (5.6%)	
2a	3 (4.3%)	2 (2.8%)	
2b	3 (4.3%)	6 (8.3%)	
Workflow (in minutes)			
Symptom onset to admission ER	204 (127-323)	207 (84-384)	0.79
Admission ER to groin puncture	120 (96-156)	126 (100-165)	0.21
Duration procedure	57 (40-93)	70 (40-100)	0.62
Symptom onset to reperfusion	390 (314-604)	439 (315-581)	0.30

Baseline variables with UFH and LMWH group. *$P<0.05$. ASPECTS indicates Alberta Stroke Program Early Computed Tomography Score; ER, emergency room; ICA, internal carotid artery; INR, international normalized ratio; LMWH, low-molecular-weight heparin; MCA-M1/M2, the first/second segment of middle cerebral artery; mTICI, modified thrombolysis in cerebral infarction; NIHSS, National Institutes of Health Stroke Scale; UFH, unfractionated heparin.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Stroke Vasc Neurol

Supplementary Table 3. Baseline demographics in minimal-dose vs low-dose group			
	Minimal-dose group (n=76)	Low-dose group (n=65)	*P* Value
Common patient characteristics			
Age, y	71 (63-78)	70 (60-78)	0.56
Male	27 (35.5%)	25 (38.5%)	0.72
Admission NIHSS	17 (13-22)	16 (12-21)	0.14
Ischemia in left hemisphere	44 (57.9%)	30 (46.2%)	0.16
Treatment with intravenous thrombolysis	34 (44.7%)	32 (49.2%)	0.59
Premorbid oral anti-thrombotic use	24 (31.6%)	26 (40.0%)	0.30
Smoke	9 (11.8%)	19 (29.2%)	0.01*
Hypertension	36 (47.4%)	28 (43.1%)	0.61
Diabetes mellitus	16 (21.1%)	16 (24.6%)	0.62
Previous stroke	6 (6.6%)	11 (16.9%)	0.05
Systolic blood pressure	142.55±23.04	142.57±24.23	0.99
Diastolic blood pressure	83.68±17.04	83.55±15.43	0.96
INR	1.03(0.98-1.12)	1.07 (0.99-1.14)	0.09
Trombocyte count	183 (144-220)	165 (125-221)	0.25
Glucose level	7.30 (6.03-9.20)	7.70 (6.75-9.28)	0.36
CHA2DS2-VASc	5 (3-5)	4 (3-5)	0.83
HASBLED	3 (2-4)	3 (3-4)	0.74
Heparin during procedure	35 (46.1%)	29 (44.6%)	0.86
Tirofiban during procedure	23 (30.3%)	13 (20.0%)	0.16
Imaging			
ASPECETS	9 (8-10)	9 (8-10)	0.12
Occlusion site			0.98
ICA	21 (27.6%)	18 (27.7%)	
MCA-M1	42 (55.3%)	35 (53.8%)	
MCA-M2	13 (17.1%)	12 (18.5%)	
Reperfusion before intervention (mTICI)			0.01*
0	58 (76.3%)	61 (93.8%)	
1	6 (7.9%)	2 (3.1%)	
2a	5 (6.6%)	0 (0.0%)	
2b	7 (9.2%)	2 (3.1%)	
Workflow (in minutes)			
Symptom onset to admission ER	220 (93-417)	198 (115-303)	0.36
Admission ER to groin puncture	113(96-151)	127 (99-185)	0.24
Duration procedure	61 (37-95)	60 (41-99)	0.48
Symptom onset to reperfusion	441 (295-624)	429 (324-558)	0.86
Baseline variables with low-dose and moderate-dose group. *P<0.05. ASPECTS indicates Alberta Stroke Program Early Computed Tomography Score; ER, emergency room; ICA, internal carotid artery; INR, international normalized ratio; MCA-M1/M2, the first/second segment of middle cerebral artery; mTICI, modified thrombolysis in cerebral infarction; NIHSS, National Institutes of Health Stroke Scale.			

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Stroke Vasc Neurol

Supplementary Table 4. Univariate analyses for the outcomes between ultra-early and 24-72h groups				
Variable	Ultra-early anticoagulation (n=111)	24-72h anticoagulation (n=30)	*P* value	OR (95% CI)
Primary outcomes				
mRS	2 (1-4)	3 (1-4)	0.43	1.33 (0.65-2.70)
sICH	1 (0.9%)	1 (3.3%)	0.38	0.26 (0.02-4.34)
Secondary outcomes				
mRS≤2	68 (61.3%)	14 (46.7%)	0.15	1.81 (0.80-4.07)
Mortality	7 (6.3%)	0 (0.0%)	0.35	NA
aICH	15 (13.5%)	9 (30.0%)	0.03	0.37 (0.14-0.94)
New ischemic stroke	7 (6.3%)	2 (6.7%)	1.00	0.94 (0.19-4.79)
aICH indicates asymptomatic intracranial hemorrhage; mRS, modified Rankin Scale; NA, not available; OR, odds ratio; sICH, symptomatic intracranial hemorrhage.				

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

Stroke Vasc Neurol

Supplementary Table 5. Univariate analyses for the outcomes between UFH and LMWH groups				
Variable	UFH group (n=69)	LMWH group (n=72)	*P* value	OR (95% CI)
Primary outcomes				
mRS	2 (1-4)	2 (1-4)	0.84	0.94 (0.53-1.68)
sICH	1 (1.4%)	1 (1.4%)	1.00	1.04 (0.06-17.03)
Secondary outcomes				
mRS≤2	41 (59.4%)	41 (56.9%)	0.77	1.11 (0.57-2.16)
Mortality	2 (2.9%)	5 (6.9%)	0.47	0.40 (0.08-2.13)
aICH	9 (13.0%)	15 (20.8%)	0.22	0.57 (0.23-1.41)
New ischemic stroke	4 (5.8%)	5 (6.9%)	1.00	0.83 (0.21-3.21)
aICH indicates asymptomatic intracranial hemorrhage; LMWH, low-molecular-weight heparin; mRS, modified Rankin Scale; OR, odds ratio; sICH, symptomatic intracranial hemorrhage; UFH, unfractionated heparin.				

Supplementary Table 6. Univariate analyses for the outcomes between minimal-dose and low-dose groups				
Variable	Minimal-dose group (n=76)	Low-dose group (n=65)	*P* value	OR (95% CI)
Primary outcomes				
mRS	2 (1-4)	2 (1-4)	0.41	0.78 (0.44-1.40)
sICH	1 (1.3%)	1 (1.5%)	1.00	0.85 (0.05-13.92)
Secondary outcomes				
mRS≤2	44 (57.9%)	38 (58.5%)	0.95	0.98 (0.50-1.91)
Mortality	4 (5.3%)	4 (4.6%)	1.00	1.15 (0.25-5.33)
aICH	13 (17.1%)	11 (16.9%)	0.98	1.01 (0.42-2.45)
New ischemic stroke	5 (6.6%)	4 (6.2%)	1.00	1.07 (0.28-4.18)
aICH indicates asymptomatic intracranial hemorrhage; mRS, modified Rankin Scale; OR, odds ratio; sICH, symptomatic intracranial hemorrhage.				

Supplementary Figure 1. Distribution of modified Rankin Scale (mRS) scores at 90 days for patients allocated to ultra-early, 24-72h and routine anticoagulation group. There was a significant shift towards better functional outcomes for ultra-early versus routine anticoagulation (adjusted common odds ratio [acOR] 2.03 [95% CI 1.20-3.44]), and a non-significant shift towards better functional outcome for 24-72h versus routine anticoagulation (acOR 1.95 [95% CI 0.89-4.30]).